ClinicalTrials.gg
CompletedNCT04546724Updated Jun 28, 2023Results posted

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

A Phase 3 interventional study of VLA1553 and Placebo in Chikungunya Virus Infection, sponsored by Valneva Austria GmbH. Completed at 44 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by Valneva Austria GmbH (part of Valneva) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Chikungunya Fever by Valneva — 2 open to participants now, 5 under way, 1 of them phase 3. Chikungunya Fever · Valneva.

Started
2020
the only one that year
Phase 3
5 of 11
none open now
Registered
2nd of 11
by date

Among the 11 studies in Chikungunya Fever by Valneva, this one is the only one that started in 2020, is one of 5 in phase 3, and was the 2nd registered.

Chikungunya Fever

88 studies on the registry are indexed under Chikungunya Fever; 21 are open to participants now.

Browse Chikungunya Fever studies →

Open to participants now

2 of the 11 studies in Chikungunya Fever by Valneva are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 8 Chikungunya Fever studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Chikungunya Fever by Valneva, or all of them as a file.
02

Study summary

This was a prospective, randomized, double-blinded, multicenter, pivotal clinical study evaluating the final dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The final dose of VLA1553 or control was administered as single immunization on Day 1. Overall, 4.128 male and female subjects aged 18 years and above were randomized into the study.

Read the detailed description

This was a prospective, double-blinded, multicenter, randomized, pivotal Phase 3 study and 4.128 participants aged 18 years or above were randomized in a 3:1 ratio to the live-attenuated CHIKV vaccine candidate (VLA1553) or placebo. The final dose of lyophilized VLA1553 or placebo was administered as a single intramuscular immunization. Subjects in this study were stratified into two age strata of 18 to 64 years and 65 years of age or above. The primary objective of the study was to evaluate the immunogenicity and safety of the final dose of VLA1553 28 days following the single immunization. Immunogenicity evaluations in the immunogenicity subset included the proportion of subjects with seroprotective neutralizing CHIKV antibody titers above a surrogate threshold indicative of protection. The surrogate of protection reasonably likely to predict clinical benefit has been established in non-human primate passive transfer studies using human sera from the Phase 1 study and was supported by sero-epidemiological studies. Safety data collection and immunogenicity were assessed until Month 6.

The first enrolled and randomized 501 subjects comprised the immunogenicity subset.

03

Conditions studied

  • Chikungunya Virus Infection

Browse trials for

Keywords

  • VLA1553
  • Chikungunya Virus Infection
  • CHIKV
  • Live-attenuated Chikungunya virus vaccine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. 18 years of age or above on the Day of screening
  2. able to provide
  3. generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests
  4. for women of :

    1. practiced an adequate method of during 30 days before screening
    2. negative serum or urine pregnancy test at screening
    3. agreed to employ adequate birth control measures for the first three months post-vaccination.

Main Exclusion Criteria:

  1. CHIKV infection in the past, including suspected CHIKV infection; was taking medication or other treatment for unresolved symptoms attributed to a previous CHIKV infection; or had participated in a clinical study involving an CHIKV vaccine
  2. acute or recent infection
  3. Subject tested positive for (HIV), surface antigen (HBsAg) or virus (HCV);
  4. within 28 days or inactivated vaccine within 14 days prior to vaccination in this study or planned to receive a vaccine within 28 days or 14 days after vaccination, respectively
  5. abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) considered by the Investigator which pose a risk for participation in the study
  6. medical history of or currently had acute or progressive, unstable or uncontrolled clinical conditions that posed a risk for participation in the study
  7. history of immune-mediated or clinically relevant arthritis / arthralgia
  8. history of in the past 5 years other than squamous cell or basal cell skin cancer. If there had been surgical excision or treatment more than 5 years ago that was considered to have achieved a cure, the subject could be enrolled.
  9. known or suspected defect of the immune system, such as subjects with congenital or acquired immunodeficiency, including infection with HIV, status post organ transplantation or immuno-suppressive therapy within 4 weeks prior to vaccination.
  10. history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known )
  11. with clinical conditions representing a contraindication to intramuscular vaccination and blood draws
  12. pregnant or lactating at the time of enrollment
  13. Donation of blood, blood fractions or plasma within 30 days or received blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or planned to donate blood or used blood products until Day 180 of the study
  14. rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating
  15. known or suspected problem with alcohol or drug abuse as determined by the Investigator
  16. any condition that, in the opinion of the Investigator, could compromise the subjects well-being, interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;
  17. committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities)
  18. Participation in another clinical study involving an investigational medicinal product (IMP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study
  19. member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4,128 participants (actual)

Study arms

  • Active comparator
    VLA1553

    Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose

    Biological: VLA1553

  • Placebo comparator
    Placebo

    Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo

    Biological: Placebo

Interventions

  • BiologicalVLA1553

    Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate; 1x10E4 TCID50 per dose

  • BiologicalPlacebo

    Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination

    Seroprotection rate, based on a surrogate of protection agreed with FDA Assay used for analysis was based on µPRNT (Micro Plaque Reduction Neutralization Test). Participants at pre-selected sites were included, if they had available Day 1 and Day 29 samples and without major protocol deviations that could impact the immune response.

    Time frame: on Day 29 after single vaccination

Secondary outcomes

  1. CHIKV-specific Neutralizing Antibody Titers

    CHIKV-specific Neutralizing Antibody Titers on Day 8, and Day 29 Postvaccination as Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) Assay

    Time frame: Until Day 180

  2. Number of Participants With Seroprotective CHIKV Antibody Level

    Seroprotection rate, based on a surrogate of protection agreed with FDA Seroprotective CHIKV Antibody Level Defined as μPRNT (Micro Plaque Reduction Neutralization Test) for Baseline Negative Subjects

    Time frame: Until Day 180

  3. Number of Participants With Seroconversion

    Seroconversion was defined as CHIKV-specific neutralizing antibody titer of ≥ 20 based on µPRNT (Micro Plaque Reduction Neutralization Test) for baseline negative subjects

    Time frame: Until Day 180

  4. Fold "Change" of CHIKV-specific Neutralizing Antibody Titers Compared to Baseline

    Fold Change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline

    Time frame: until Day 180

  5. Number of Participants Reaching an X-fold Change in CHICKV-specific Neutralizing Antibody Titer Compared to Baseline

    Number of Participants Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline

    Time frame: until Day 180

  6. Unsolicited AEs

    Number of Participants with Unsolicited Adverse Events

    Time frame: Until Day 29

  7. Solicited Injection Site AEs

    Number of Participants with solicited injection site reactions

    Time frame: within 10 days post-vaccination

  8. Solicited Systemic AEs

    Number of Participants with solicited systemic reactions

    Time frame: within 10 days post-vaccination

  9. Adverse Events

    Number of Participants with any Adverse Events

    Time frame: until Day 180

  10. Related Adverse Events

    Number of Participants with any related Adverse Events

    Time frame: until Day 180

  11. Serious Adverse Event

    Number of Participants with any Serious Adverse Events

    Time frame: until Day 180

  12. Related Serious Adverse Event

    Number of Participants with any Related Serious Adverse Events

    Time frame: until Day 180

  13. Adverse Event of Special Interest

    Number of Participants with any Adverse Event of Special Interest AESI Definition: The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration: 1. Fever (≥38.0°C \[100.4°F\] measured orally) and 2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \[foot plant\] and edema of the face and extremities), polyadenopathies; and 3. Onset of symptoms 2 to 21 days after vaccination and 4. Duration of event ≥3 days.

    Time frame: within 21 days post-vaccination

  14. Related Adverse Event of Special Interest

    Number of Participants with any Related Adverse Event of Special Interest AESI Definition: The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration: 1. Fever (≥38.0°C \[100.4°F\] measured orally) and 2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \[foot plant\] and edema of the face and extremities), polyadenopathies; and 3. Onset of symptoms 2 to 21 days after vaccination and 4. Duration of event ≥3 days.

    Time frame: within 21 days post-vaccination

07

Results

Posted Jul 25, 2022

Participant flow

Participant flow — Overall Study
MilestoneVLA1553Placebo
Started30821033
Completed2724920
Not completed358113
Withdrew: Withdrawal by subject14541
Withdrew: Adverse event11
Withdrew: Lost to follow-up18663
Withdrew: Physician decision82
Withdrew: Death21
Withdrew: Subject has been out of town10
Withdrew: Subject is incarcerated20
Withdrew: Subject is relocating124
Withdrew: Subject in another study11

Outcome measures

PrimaryNumber of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination

Seroprotection rate, based on a surrogate of protection agreed with FDA Assay used for analysis was based on µPRNT (Micro Plaque Reduction Neutralization Test). Participants at pre-selected sites were included, if they had available Day 1 and Day 29 samples and without major protocol deviations that could impact the immune response.

Time frame:
on Day 29 after single vaccination
Reported as:
Count of participants · Participants
Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination
ParticipantsVLA1553 18-64 YearsPlacebo 18-64 YearsVLA1553 ≥65 YearsPlacebo ≥65 Years
Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination2040590
SecondaryCHIKV-specific Neutralizing Antibody Titers

CHIKV-specific Neutralizing Antibody Titers on Day 8, and Day 29 Postvaccination as Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) Assay

Time frame:
Until Day 180
Reported as:
Geometric mean · Antibody Titers
CHIKV-specific Neutralizing Antibody Titers
Antibody TitersVLA1553 18-64 YearsPlacebo 18-64 YearsVLA1553 ≥65 YearsPlacebo ≥65 Years
Visit 2 - Day 813.6 (12.22 to 15.23)10.2 (9.92 to 10.50)13.4 (11.05 to 16.31)10.0 (10.0 to 10.0)
Visit 3 - Day 293273.7 (2860.93 to 3746.04)10.1 (9.89 to 10.33)3688.8 (2938.94 to 4630.10)10.0 (10.0 to 10.0)
Visit 4 - Day 851068.7 (934.77 to 1221.82)10.0 (10.0 to 10.0)1140.9 (942.97 to 1380.31)10.7 (9.71 to 11.78)
Visit 5 - Day 180755.1 (656.01 to 869.16)10.0 (10.0 to 10.0)742.8 (578.36 to 954.0)10.0 (10.0 to 10.0)
SecondaryNumber of Participants With Seroprotective CHIKV Antibody Level

Seroprotection rate, based on a surrogate of protection agreed with FDA Seroprotective CHIKV Antibody Level Defined as μPRNT (Micro Plaque Reduction Neutralization Test) for Baseline Negative Subjects

Time frame:
Until Day 180
Reported as:
Count of participants · Participants
Number of Participants With Seroprotective CHIKV Antibody Level
ParticipantsVLA1553 18-64 YearsPlacebo 18-64 YearsVLA1553 ≥65 YearsPlacebo ≥65 Years
Visit 2 - Day 82020
Visit 4 - Day 851890520
Visit 5 - Day 1801780550
SecondaryNumber of Participants With Seroconversion

Seroconversion was defined as CHIKV-specific neutralizing antibody titer of ≥ 20 based on µPRNT (Micro Plaque Reduction Neutralization Test) for baseline negative subjects

Time frame:
Until Day 180
Reported as:
Count of participants · Participants
Number of Participants With Seroconversion
ParticipantsVLA1553 18-64 YearsPlacebo 18-64 YearsVLA1553 ≥65 YearsPlacebo ≥65 Years
Visit 3 - Day 292051590
Visit 5 - Day 1801810570
SecondaryFold "Change" of CHIKV-specific Neutralizing Antibody Titers Compared to Baseline

Fold Change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline

Time frame:
until Day 180
Reported as:
Mean · fold increase
Fold "Change" of CHIKV-specific Neutralizing Antibody Titers Compared to Baseline
fold increaseVLA1553 18-64 YearsPlacebo 18-64 YearsVLA1553 ≥65 YearsPlacebo ≥65 Years
Visit 3 - Day 29460.27 ± 384.0521.02 ± 0.140507.70 ± 412.4671.00 ± 0.000
Visit 5 - Day 180108.81 ± 97.2381.00 ± 0.000102.09 ± 79.4331.00 ± 0.000
SecondaryNumber of Participants Reaching an X-fold Change in CHICKV-specific Neutralizing Antibody Titer Compared to Baseline

Number of Participants Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline

Time frame:
until Day 180
Reported as:
Count of participants · Participants
Number of Participants Reaching an X-fold Change in CHICKV-specific Neutralizing Antibody Titer Compared to Baseline
ParticipantsVLA1553 18-64 YearsPlacebo 18-64 YearsVLA1553 ≥65 YearsPlacebo ≥65 Years
Visit 3 - Day 29: Subjects reaching 4-fold increase2050590
Visit 3 - Day 29: Subjects reaching 8-fold increase2050590
Visit 3 - Day 29: Subjects reaching 16-fold increase2040590
Visit 3 - Day 29: Subjects reaching 64-fold increase2000570
Visit 5 - Day 180: Subjects reaching 4-fold increase1810570
Visit 5 - Day 180: Subjects reaching 8-fold increase1810560
Visit 5 - Day 180: Subjects reaching 16-fold increase1770550
Visit 5 - Day 180: Subjects reaching 64-fold increase1060350
SecondaryUnsolicited AEs

Number of Participants with Unsolicited Adverse Events

Time frame:
Until Day 29
Reported as:
Count of participants · Participants
Unsolicited AEs
ParticipantsVLA1553Placebo
Unsolicited AEs687138
SecondarySolicited Injection Site AEs

Number of Participants with solicited injection site reactions

Time frame:
within 10 days post-vaccination
Reported as:
Count of participants · Participants
Solicited Injection Site AEs
ParticipantsVLA1553Placebo
Any Solicited Injection Site Adverse Event463115
Tenderness32884
Pain19138
Erythema/Redness4615
Induration448
Swelling218
SecondarySolicited Systemic AEs

Number of Participants with solicited systemic reactions

Time frame:
within 10 days post-vaccination
Reported as:
Count of participants · Participants
Solicited Systemic AEs
ParticipantsVLA1553Placebo
Any Solicited Systemic Adverse Event1547278
Headache969151
Fatigue879130
Myalgia73576
Arthralgia52050
Fever4148
Nausea34558
Rash705
Vomiting5810
SecondaryAdverse Events

Number of Participants with any Adverse Events

Time frame:
until Day 180
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsVLA1553Placebo
Mild1287336
Moderate532112
Severe10414
SecondaryRelated Adverse Events

Number of Participants with any related Adverse Events

Time frame:
until Day 180
Reported as:
Count of participants · Participants
Related Adverse Events
ParticipantsVLA1553Placebo
Related Adverse Events1575322
SecondarySerious Adverse Event

Number of Participants with any Serious Adverse Events

Time frame:
until Day 180
Reported as:
Count of participants · Participants
Serious Adverse Event
ParticipantsVLA1553Placebo
Serious Adverse Event468
SecondaryRelated Serious Adverse Event

Number of Participants with any Related Serious Adverse Events

Time frame:
until Day 180
Reported as:
Count of participants · Participants
Related Serious Adverse Event
ParticipantsVLA1553Placebo
Related Serious Adverse Event20
SecondaryAdverse Event of Special Interest

Number of Participants with any Adverse Event of Special Interest AESI Definition: The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration: 1. Fever (≥38.0°C \[100.4°F\] measured orally) and 2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \[foot plant\] and edema of the face and extremities), polyadenopathies; and 3. Onset of symptoms 2 to 21 days after vaccination and 4. Duration of event ≥3 days.

Time frame:
within 21 days post-vaccination
Reported as:
Count of participants · Participants
Adverse Event of Special Interest
ParticipantsVLA1553Placebo
Adverse Event of Special Interest101
SecondaryRelated Adverse Event of Special Interest

Number of Participants with any Related Adverse Event of Special Interest AESI Definition: The following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration: 1. Fever (≥38.0°C \[100.4°F\] measured orally) and 2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \[foot plant\] and edema of the face and extremities), polyadenopathies; and 3. Onset of symptoms 2 to 21 days after vaccination and 4. Duration of event ≥3 days.

Time frame:
within 21 days post-vaccination
Reported as:
Count of participants · Participants
Related Adverse Event of Special Interest
ParticipantsVLA1553Placebo
Related Adverse Event of Special Interest91

Adverse events

Collected over Day 180. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VLA15532/3,082 (0.1%)46/3,082 (1.5%)1,721/3,082 (55.8%)
Placebo1/1,033 (0.1%)8/1,033 (0.8%)373/1,033 (36.1%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventVLA1553Placebo
Suicidal ideationPsychiatric disorders3/30821/1033
DepressionPsychiatric disorders3/30820/1033
COVID-19Infections and infestations1/30821/1033
PneumoniaInfections and infestations2/30821/1033
AnxietyPsychiatric disorders0/30821/1033
Gastrointestinal haemorrageGastrointestinal disorders0/30821/1033
Cerebellar haemorrhageNervous system disorders0/30821/1033
Kidney infectionInfections and infestations0/30821/1033
Hip fractureInjury, poisoning and procedural complications0/30821/1033
Mental status changesPsychiatric disorders0/30821/1033
Most frequent other events
Showing 10 of 17
Most frequent other events
EventVLA1553Placebo
HeadacheNervous system disorders986/3082160/1033
FatigueGeneral disorders886/3082137/1033
MyalgiaMusculoskeletal and connective tissue disorders750/308282/1033
ArthralgiaMusculoskeletal and connective tissue disorders554/308263/1033
PyrexiaGeneral disorders427/308213/1033
Injection site painGeneral disorders413/3082101/1033
NauseaGastrointestinal disorders359/308263/1033
RashSkin and subcutaneous tissue disorders82/308212/1033
VomitingGastrointestinal disorders66/308214/1033
COVID-19Infections and infestations59/308222/1033

Baseline characteristics

Age, Continuous
Age, Continuous(years)VLA1553PlaceboTotal
Mean45.1 ± 15.4445.0 ± 15.5945.0 ± 15.47
Sex: Female, Male
Sex: Female, Male(Participants)VLA1553PlaceboTotal
Female16825692251
Male14004641864
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VLA1553PlaceboTotal
American Indian or Alaska Native27532
Asian511768
Black or African American451122573
Native Hawaiian or other Pacific Islander13518
White24568533309
Other8431115
08

Study locations

44 sites
  • Accelerated Enrollment Solutions (AES)
    Chandler, Arizona 85224, United States
  • Accelerated Enrollment Solutions (AES)
    Phoenix, Arizona 85020, United States
  • Alliance for Multispecialty Research (AMR)
    Tempe, Arizona 85283, United States
  • ELITE Research Network (ELITE)
    Little Rock, Arkansas 72204, United States
  • Velocity Clinical Research, Chula Vista
    Chula Vista, California 91911, United States
  • Accelerated Enrollment Solutions (AES)
    San Diego, California 92108, United States
  • Accel Research Sites - DeLand
    DeLand, Florida 32720, United States
  • ELITE Research Network (ELITE)
    Hallandale Beach, Florida 33009, United States
  • Meridien Research - Maitland
    Maitland, Florida 32751, United States
  • Accelerated Enrollment Solutions (AES)
    Melbourne, Florida 32934, United States
  • Suncoast Research Group, LLC
    Miami, Florida 33135, United States
  • ELITE Research Network (ELITE)
    North Miami Beach, Florida 33135, United States
  • Jacksonville Center for Clinical Research, LTD dba St. Johns Center for Clinical Research
    Ponte Vedra, Florida 32081, United States
  • Synexus - The Villages
    The Villages, Florida 32162, United States
  • ELITE Research Network (ELITE)
    Meridian, Idaho 83642, United States
  • Accelerated Enrollment Solutions (AES)
    Chicago, Illinois 60602, United States
  • Accelerated Enrollment Solutions (AES)
    Peoria, Illinois 61614, United States
  • Alliance for Multispecialty Research (AMR)
    El Dorado, Kansas 67042, United States
  • Alliance for Multispecialty Research (AMR)
    Newton, Kansas 67114, United States
  • Alliance for Multispecialty Research (AMR)
    Wichita, Kansas 67207, United States
  • Alliance for Multispecialty Research (AMR)
    Lexington, Kentucky 40509, United States
  • AMR - New Orleans - Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • Alliance for Multispecialty Research (AMR)
    Kansas City, Missouri 64114, United States
  • Meridian Clinical Research - Grand Island
    Grand Island, Nebraska 68803, United States
  • Platinum Research Network (Platinum)
    Omaha, Nebraska 68134, United States
  • Accelerated Enrollment Solutions (AES)
    Omaha, Nebraska 68144, United States
  • Alliance for Multispecialty Research (AMR)
    Las Vegas, Nevada 89119, United States
  • Meridian Clinical Research
    Endwell, New York 13760, United States
  • Rochester Clinical Research
    Rochester, New York 14609, United States
  • Lucas Research
    Morehead City, North Carolina 28557, United States
  • ELITE Research Network (ELITE)
    Wilmington, North Carolina 28403, United States
  • Accelerated Enrollment Solutions (AES)
    Cincinnati, Ohio 45236, United States
  • ELITE Research Network (ELITE)
    Oklahoma City, Oklahoma 73112, United States
  • Velocity Clinical Research - Medford
    Medford, Oregon 97504, United States
  • Synexus - Anderson
    Anderson, South Carolina 29621, United States
  • Vitalink Research - Anderson
    Anderson, South Carolina 29621, United States
  • Alliance for Multispecialty Research (AMR)
    Knoxville, Tennessee 37920, United States
  • Tekton Research - Beaumont
    Beaumont, Texas 77706, United States
  • PanAmerican Clinical Research - US Headquarter
    Brownsville, Texas 78521, United States
  • Velocity Clinical Research - Austin
    Cedar Park, Texas 78613, United States
  • Research Your Health, LLC
    Plano, Texas 75093, United States
  • ELITE Research Network (ELITE)
    Tomball, Texas 77375, United States
  • ELITE Research Network (ELITE)
    West Jordan, Utah 84088, United States
  • Alliance for Multispecialty Research (AMR)
    Norfolk, Virginia 23507, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in May 2021, 8 months.

Results were first posted in Jul 2022, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2020
First posted
Sep 14, 2020
StartActual
Sep 17, 2020
Primary completionActual
May 19, 2021
CompletionActual
Oct 15, 2021
Results first posted
Jul 25, 2022
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04546724
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Sep 17, 2020
Primary completion
May 19, 2021
Completion
Oct 15, 2021
Results posted
Jul 25, 2022
Last update
Jun 28, 2023

Study contacts

Valneva Clinical Development
study chair · Valneva Austria GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chikungunya vaccine

Start the discussion